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Objectives: Differences in mortality rates previously reported in criti-
cally ill patients with coronavirus disease 2019 have increased the 
need for additional data on mortality and risk factors for death. We 
conducted this study to describe length of stay, mortality, and risk 
factors associated with in-hospital mortality in mechanically ventilated 
patients with coronavirus disease 2019.
Design: Observational study.
Setting: Two urban, academic referral hospitals in Indianapolis, 
Indiana.
Patients or Subjects: Participants were critically ill patients 18 years 
old and older, admitted with coronavirus disease 2019 between 
March 1, 2020, and April 27, 2020.
Interventions: None.
Measurements and Main Results: Outcomes included in-hospital mortal-
ity, duration of mechanical ventilation, and length of stay. A total of 242 
patients were included with mean age of 59.6 years (sd, 15.5 yr), 41.7% 
female and 45% African American. Mortality in the overall cohort was 
19.8% and 20.5% in the mechanically ventilated subset. Patients who 
died were older compared with those that survived (deceased: mean 
age, 72.8 yr [sd, 10.6 yr] vs patients discharged alive: 54.3 yr [sd, 14.8 
yr]; p < 0.001 vs still hospitalized: 59.5 yr [sd, 14.4 yr]; p < 0.001) and 
had more comorbidities compared with those that survived (deceased: 
2 [0.5–3] vs survived: 1 [interquartile range, 0–1]; p = 0.001 vs still 
hospitalized: 1 [interquartile range, 0–2]; p = 0.015). Older age and end-
stage renal disease were associated with increased hazard of in-hospital 
mortality: age 65–74 years (hazard ratio, 3.1 yr; 95% CI, 1.2–7.9 yr), age 
75+ (hazard ratio, 4.1 yr; 95% CI, 1.6–10.5 yr), and end-stage renal 
disease (hazard ratio, 5.9 yr; 95% CI, 1.3–26.9 yr). The overall median 
duration of mechanical ventilation was 9.3 days (interquartile range, 5.7–
13.7 d), and median ICU length of stay in those that died was 8.7 days 
(interquartile range, 4.0–14.9 d), compared with 9.2 days (interquartile 
range, 4.0–14.0 d) in those discharged alive, and 12.7 days (interquartile 
range, 7.2–20.3 d) in those still remaining hospitalized.
Conclusions: We found mortality rates in mechanically ventilated 
patients with coronavirus disease 2019 to be lower than some previ-
ously reported with longer lengths of stay.
Key Words: coronavirus disease 2019; critical illness; respiratory 
failure
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19), has created a global public health emergency 
(1) due to its rapid spread and significant morbidity and mortal-
ity. More than 11 million cases of COVID-19 have been identified 
worldwide (1), and as of July 10, 2020, there have been 3.1 million 
confirmed cases and over 130,000 deaths in the United States (2). 
Older individuals and patients with cardiovascular disease, 
chronic lung disease, hypertension, and diabetes are at particular 
risk for death from COVID-19, often due to the development of 
severe acute respiratory distress syndrome (ARDS) (3–5).
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The mortality of critically ill mechanically ventilated patients 
with COVID-19 was reported as high as 88–97% (3, 5–8). A recent 
study reported mortality rates of 30.9%, but whether these low 
rates are seen at other centers is not known (9).
Further data on mortality and length of stay are needed to 
advance the global understanding of outcomes in critically ill 
COVID-19 patients. We carried out this analysis with the primary 
aim to describe the length of stay, mortality, and risk factors asso-
ciated with death in ICU patients with COVID-19 infection.
MATERIALS AND METHODS
This observational study was conducted at two large urban 
academic centers affiliated with Indiana University School of 
Medicine: Indiana University Health Methodist Hospital, an 802-
bed quaternary care referral center, and Eskenazi Health, a 336-
bed safety net hospital. All consecutive patients admitted to the 
ICUs with a positive result by SARS-CoV-2 nasopharyngeal swab 
polymerase chain reaction test from March 1, 2020, to April 27, 
2020, were included. Patients under the age of 18 were excluded. 
Clinical outcomes were collected until April 29, 2020. The primary 
outcomes were in-hospital mortality, duration of mechanical ven-
tilation, and length of ICU and hospital stay. The study received 
approval from the local Institutional Review Board.
Data Collection
Data were extracted from hospital electronic medical systems 
(Cerner PowerChart, Epic Health Systems) and entered directly 
into a REDCap database. Records were randomly audited to reduce 
the risk of measurement error or bias. Data included patient demo-
graphics, comorbidities, Acute Physiology and Chronic Health 
Evaluation (APACHE) II score (10), vital signs and laboratory 
results (from first 24 hr of ICU admission), including SARS-CoV-2 
test results, and dates of admission, discharge, and death. APACHE 
II was calculated using values from the first 24 hours of admission 
to the ICU. If the patient was readmitted during the study follow-
up period, laboratory data from the initial ICU admission was 
used. For patients transferred to the two hospitals, data collection 
began at time of ICU admission to our system.
Statistical Analysis
Demographic and clinical characteristics were compared between 
patients who were discharged alive, those still admitted at the end 
of the follow-up period, and those who died in the hospital using 
analysis of variance (normal data) and Wilcoxon rank-sum tests 
(skewed data) for continuous outcomes or Fisher exact test for cat-
egorical variables. For significant variables, we explored pairwise 
comparisons and adjusted for multiple comparisons using the 
stepdown Bonferroni method. Summary statistics were provided 
for mechanically ventilated patients and those who were not ven-
tilated. Variables with significant group differences in univariate 
analysis (with the exception of insurance as it was collinear with 
age) were included in a cause-specific Cox’s proportional hazards 
model to identify risk factors associated with in-hospital mortality. 
For this model, the event of interest was time from ICU admission 
to death with a competing event as time to discharge. Patients still 
in the hospital were censored.
RESULTS
Six-hundred forty-four consecutive patients with COVID-19 were 
admitted from March 1, 2020, to April 29, 2020. Two-hundred 
forty-two were ICU admissions (including 2% [5/242] transferred 
from other hospitals) and comprised the study cohort (Figure E1 
in the Supplemental Digital Content http://links.lww.com/CCX/
A283). Demographics and clinical characteristics for the cohort 
are presented in Table  1. The mean age of the cohort was 59.6 
years (sd, 15.5 yr), 41.7% were female and 45% African American. 
Hypertension (61.6%), obesity (56.4%), diabetes mellitus (43%), 
and tobacco use (26.9%) were the most frequent comorbid condi-
tions. The median APACHE II score calculated using values from 
the first 24 hours of ICU admission was 19 (interquartile range 
[IQR], 13–26), and median Charlson Comorbidity Index (11) was 
1 (IQR, 0–2). The mean Pao2:Fio2 ratio for the cohort was 116.6 (sd, 
77.6). Table  2 provides additional laboratory and hemodynamic 
characteristics of the cohort by mechanical ventilation status.
Differences in Characteristics Between Patients That 
Died, Survived, or Remained Admitted
Table  1 compares clinical characteristics and comorbidities of 
patients who died, discharged alive, or were still admitted at the 
end of the study period, including pairwise p values adjusted for 
multiple comparisons. Patients who died were older compared 
with those that survived (deceased: mean age, 72.8 yr [sd, 10.6 
yr] vs patients discharged alive: 54.3 yr [sd, 14.8 yr]; p < 0.001 
and vs still hospitalized: 59.5 yr [sd, 14.4 yr]; p < 0.001). Patients 
that died also had more comorbidities as assessed by the Charlson 
Comorbidity Index compared with patients who were alive 
(deceased: 2 [0.5–3] vs survived: 1 [IQR, 0–1]; p = 0.001 vs still 
hospitalized: 1 [IQR, 0–2]; p = 0.015). Median APACHE II scores 
were higher in patients that died (24 [IQR, 16–31]) versus those 
discharged alive (16 [IQR, 11–23]; p < 0.001) or those still in the 
hospital (20 [IQR, 12–27]; p = 0.015).
Mortality and Length of Stay Outcomes
Mechanical ventilation occurred in 76.4% of patients (185/242) 
in the overall cohort (Table  3). Mortality in the overall cohort 
was 19.8% (48/242) and 20.5% (38/185) among mechanically 
ventilated patients. There were no differences in mortality rates 
between the two health centers. The median duration of mechani-
cal ventilation in the overall cohort was 9.3 days (IQR, –5.7 to 13.7 
d). In patients that died, median ICU length of stay was 8.7 days 
(IQR, 4.0–14.9 d), compared with 9.2 days (IQR, 4.0–14.0 d) in 
those discharged alive, and 12.7 days (IQR, 7.2–20.3 d) in those 
still admitted at the end of the follow-up period (Table 3).
Risk Factors Associated With Mortality
Older age and end-stage renal disease (ESRD) were associated 
with increased hazard of in-hospital mortality: age 65–74 years 
(hazard ratio [HR], 3.1 yr; 95% CI, 1.2–7.9 yr; p = 0.021), age 75+ 
(HR, 4.1 yr; 95% CI, 1.6–10.5 yr; p = 0.003) compared with those 
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TABLE 1. Characteristics of ICU Patients With Coronavirus Disease 2019 (n = 242)
Variable
All Patients  
(n = 242)
Patients That  
Discharged  
Alive (n = 116)
Patient Still  
Admitted in  
Hospital (n = 78)
Patients  
That Died  
(n = 48) p
Age, yr, mean (sd) 59.6 (15.5) 54.3 (14.8) 59.5 (14.4) 72.8 (10.6) < 0.001 (a< 0.001, b< 0.001, c0.0099)
Female, n (%) 101 (41.7) 48 (41.4) 32 (41.0) 21 (43.8) 0.955
Race, n (%)d     0.003 (a0.091, b0.001, c0.123)
 Caucasian 75 (31.3) 35 (30.7) 22 (28.2) 18 (37.5)  
 African American 108 (45.0) 54 (47.4) 27 (34.6) 27 (56.3)  
 Hispanic/Latino 43 (17.9) 19 (16.7) 23 (29.5) 1 (2.1)  
 Other 14 (5.8) 6 (5.3) 6 (7.7) 2 (4.2)  
Insurance, n (%)     < 0.001 (a< 0.001, b0.026, c0.026)
 Medicare 65 (27.0) 16 (13.8) 21 (27.3) 28 (58.3)  
 Medicaid 36 (14.9) 16 (13.8) 15 (19.5) 5 (10.4)  
 Medicare and Medicaid 26 (10.8) 9 (7.8) 11 (14.3) 6 (12.5)  
 Commercial 66 (27.4) 45 (38.8) 15 (19.5) 6 (12.5)  
 Self-pay 27 (11.2) 16 (13.8) 10 (13.0) 1 (2.1)  
 Other 21 (8.7) 14 (12.1) 5 (6.5) 2 (4.2)  
Comorbiditiese, n (%)
 Hypertension 149 (61.6) 66 (56.9) 46 (59.0) 37 (77.1) 0.045 (a0.061, b0.105, c0.882)
 Diabetes mellitus 104 (43.0) 46 (39.7) 38 (48.7) 20 (41.7) 0.461
 Tobacco use 65 (26.9) 29 (25.0) 16 (20.5) 20 (41.7) 0.033 (a0.080, b0.044, c0.499)
 Asthma 34 (14.0) 18 (15.5) 8 (10.3) 8 (16.7) 0.495
 Chronic kidney disease 35 (14.5) 10 (8.6) 10 (12.8) 15 (31.3) 0.002 (a0.002, b0.040, c0.349)
 End-stage renal disease 8 (3.3) 0 (0.0) 4 (5.1) 4 (8.3) 0.003 (a0.020, b0.050, c0.479)
 Coronary artery disease 28 (11.6) 12 (10.3) 7 (9.0) 9 (18.8) 0.240
 Congestive heart failure 31 (12.8) 14 (12.1) 10 (12.8) 7 (14.6) 0.907
 Obstructive sleep apnea 35 (14.5) 13 (11.2) 12 (15.4) 10 (20.8) 0.256
 Chronic obstructive  
 pulmonary disease
22 (9.1) 9 (7.8) 3 (3.8) 10 (20.8) 0.008 (a0.058, b0.013, c0.365)
Obesityf     0.052
 Body mass index < 30 96 (43.6) 41 (39.0) 28 (40.0) 27 (60.0)  
 Body mass index ≥ 30 124 (56.4) 64 (61.0) 42 (60.0) 18 (40.0)  
 Charlson Comorbidity Indexg,  
 median (IQR)
1 (0–2) 1 (0–1) 1 (0–2) 2 (0.5–3) 0.001 (a0.001, b0.012, c0.301)
Severity of illness
 Acute Physiology and Chronic  
 Health Evaluation IIh at ICU  
 admission, median (IQR)
19 (13–26) 16 (11–23) 20 (12–27) 24 (16–31) < 0.001 (a< 0.001, b0.015, c0.062)
 Pao2:Fio2, mean (sd) 116.6 (77.6) 136.8 (92.2) 99.2 (54.5) 102.0 (65.5) 0.007 (
a0.044, b0.022, c0.986)
IQR = interquartile range.
Pairwise p values adjusted for multiple comparisons are as follows: 
aDeceased vs discharged alive.
bDeceased vs still hospitalized.
cDischarged alive vs still admitted.
dRace was available for 163 subjects.
eComorbidities assessed using diagnoses recorded in the medical record.
fBody mass index was available for 150 subjects.
gCharlson Comorbidity Index predicts mortality over 10 yr.
hAcute Physiology and Chronic Health Evaluation calculated using clinical data from first 24 hr of ICU admission.
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TABLE 2. Laboratory Values, Oxygenation, and Hemodynamic Characteristics of Patients 
Admitted with Novel Coronavirus on Day of ICU Admissiona
Variable Total (n = 242)
Mechanical  
Ventilation (n = 185)
No Mechanical  
Ventilation (n = 57)
All ICU patients
 Sodium, mmol/L, median (IQR) 137.0 (135.0–140.0) 137.0 (135.0–140.0) 137.0 (136.0–140.0)
 WBC count × 109/L, median (IQR) 8.7 (6.6–12.7) 8.9 (6.7–13.0) 7.8 (6.5–10.1)
 Hematocrit %, median (IQR) 37.0 (32.0–41.3) 37.0 (31.4–40.8) 38.2 (34.5–41.7)
 Platelet count × 103, median (IQR) 208.0 (151.0–255.5) 207.5 (149.0–251.0) 225.0 (175.0–266.0)
 Creatinine, mg/dL, median (IQR) 1.1 (0.8–1.9) 1.2 (0.8–1.9) 1.1 (0.8–1.9)
 pH, median (IQR) 7.4 (7.3–7.4) 7.4 (7.3–7.4) 7.4 (7.3–7.4)
 Pao2, mm Hg, median (IQR) 71.0 (58.0–95.0) 71.0 (58.0–97.5) 65.0 (43.0–81.0)
 Mean arterial pressure, mm Hg, median (IQR) 101.0 (90.0–115.0) 102.5 (90.0–117.0) 96.0 (88.0–111.0)
 Pao2/Fio2 ratio, median (IQR) 93.8 (69.0–135.0) 90.0 (68.0–128.9) 145.5 (91.7–185.7)
 Presence of shock, n (%) 46 (19.0) 41 (22.2) 5 (8.8)
IQR = interquartile range.
aData presented is from laboratory values, arterial blood gas results, vitals, and other components of the electronic medical record (first 24 hr of ICU admission).
TABLE 3. Mortality Outcomes and Length of Stay for ICU Patients With Coronavirus Disease 
2019 (n = 242)
Variable
Total  
(n = 242)
Mechanically  
Ventilated (n = 185)
Not Mechanically  
Ventilated (n = 57)
All patients in cohort (n = 242)
 Mechanically ventilated, n (%) 185 (76.4) 185 (100.0) 0 (0.0)
 Time from ICU admission to mechanical  
ventilation, hr, median (IQR)
0.5 (0–7.4) 0.4 (0–7.4) —
 Duration of mechanical ventilation, d, median (IQR) 9.3 (5.7–13.7) 9.3 (5.7–13.7) 0 (0–0)
Disposition status, n (%)
 Died (total) 48 (19.8) 38 (20.5) 10 (17.5)
 Remain admitted in hospital or ICU 78 (32.2) 66 (35.7) 12 (21.0)
 Discharged alive 116 (47.9) 81 (43.8) 35 (61.4)
Patients who died (n = 48) (n = 38) (n = 10)
 Died in ICU, n (%) 42 (87.5) 38 (100.0) 4 (40.0)
 Died in hospital, n (%) 6 (12.5) 0 (0.0) 6 (60.0)
 ICU LOSa, d, median (IQR) 8.7 (4.0–14.9) 10.5 (7.0–15.8) 3.3 (2.0–6.3)
 Time from hospital admission to death, da, median (IQR) 29.5 (22.5–33) 31 (23–34) 28 (20–30)
 Duration of mechanical ventilation, d, median (IQR) 8.8 (5.4–15.1) 8.8 (5.4–15.1) 0 (0–0)
Patients discharged alive, median (IQR) (n = 116) (n = 81) (n = 35)
 ICU LOS, d 9.2 (4.0–14.1) 10.8 (7.5–15.2) 2.8 (1.7–5.0)
 Hospital LOS 30 (23–34) 31 (26–34) 27 (18–32)
 Duration of mechanical ventilation, d 8.7 (4.9–11.4) 8.7 (4.9–11.4) 0 (0–0)
Patients still in hospital or ICU, median (IQR) (n = 78) (n = 66) (n = 12)
 ICU LOS, d 12.7 (7.2–20.3) 16.1 (9.3–21.3) 2.6 (2.1–3.3)
 Hospital LOS 15.5 (7–24) 18.5 (10–27) 5 (3–6)
 Duration of mechanical ventilation, d 10.9 (7.2–14.9) 10.9 (7.2–14.9) 0 (0–0)
IQR = interquartile range, LOS = length of stay.
Dash indicates data cannot be calculated because these are nonventilated subjects.
aLOS and time to death were calculated from time of admission to hospital and/or ICU until time of discharge or death.
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younger than age 65, and ESRD (HR, 5.9; 95% CI, 1.3–26.9; p = 
0.021). In our cause-specific Cox’s proportional hazard model, 
race, Charlson Comorbidity Index, and severity of illness by 
APACHE II were not significantly associated with increased odds 
of hospital mortality (Table 4).
DISCUSSION
In this study, we report a mortality rate of approximately 20% in 
mechanically ventilated COVID-19 patients, lower than recently 
published reports (3, 5–9). Furthermore, the mortality in our 
cohort is even lower than reported 28-day mortality of 35–46% 
for mild to severe ARDS (12).
Our mortality results are likely due to the surge in COVID-19 
patients occurring later in Indiana than in other places, provid-
ing us the opportunity to learn from experiences at other centers. 
In addition, our medical system was not highly stressed. Due to 
a lack of strain on ventilator resources, clinicians at our hospi-
tals elected to intubate patients early, as evidenced by 76% of the 
COVID-19-related ICU admissions receiving invasive ventilation. 
In contrast to other centers, we saw a relatively rapid but brief 
increase in COVID-19 ICU cases beginning in mid-March, peak-
ing in early April (Figure E2 in the Supplemental Digital Content 
http://links.lww.com/CCX/A283), and subsequently declining. 
Near the peak, only 58% of ICU beds and 27% of ventilators in the 
state were being used. This flattening of the curve can be attributed 
to a lower population density and early implementation of social 
distancing restrictions, allowing the medical system to effectively 
deal with the COVID-19 surge. This relationship between medical 
system capacity, the number of patients, and outcomes have been 
well described in the context of pandemic influenza (13, 14).
Our study is smaller compared with other cohorts limiting our 
ability to draw conclusions about mortality risk factors, although, 
like others, we found older age to be a significant risk factor, while 
patients identified as African American or Hispanic did not have 
increased risk of in-hospital mortality. We did not identify spe-
cific treatments, which led to a decreased mortality in our venti-
lated COVID-19 patients. Such work will require more granular 
analysis. However, we believe that sites able to prepare resources 
without getting overwhelmed with disease surges will show simi-
lar experiences. Our cumulative experience at Indiana University 
counterbalances prior published reports leading to the public per-
ception that ventilatory support in COVID-19 patients frequently 
results in death, causing some to question the utility of mechanical 
ventilation in these patients.
CONCLUSIONS
In conclusion, we found lower mortality among mechanically 
ventilated COVID-19 patients than recently reported by others. 
This highlights that clinical experience with COVID-19 will vary 
widely across the country, which may be due to differences in pub-
lic health practices, local medical practices, or resource availabil-
ity. Ascertainment of comprehensive and accurate statistics will be 
important when developing policies and guidelines regarding the 
COVID-19 pandemic (15).
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